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Abstract— Metal-based nanoparticles such as gold, silver, platinum, and bismuth have been widely investigated for radiotherapeutic 
application. Basic understanding of the cellular interaction of the nanoparticles with the biological materials is crucial to ensure 
future clinical use. In this study, the cytotoxicity, cellular uptake, and generation of reactive oxygen species (ROS) induced by BiONPs 
were investigated prior elucidating the feasibility of BiONPs for radiotherapy application using megavoltage photon and electron 
beams. The BiONPs of diameter sizes 60, 70, 80 and 90 nm at concentrations within a range of 0.5 to 0.00005 mMol/L were tested on 
MCF-7, MDA-MB-231, and NIH/3T3 cells lines. The cytotoxicity results exhibit minimal cell death constituting less than 20 % of 
mortality on average. The ROS generation by BiONPs alone is found to be negligible as the ROS levels were slightly lower and higher 
than 100% of positive control. The increment of cellular nanoparticles uptake from a range of 1.50 % to 34.10 % indicates that 
BiONPs were internalized and bound to the surface of the cells. Sequencing from the results, 60 nm BiONPs are found to be the most 
suitable to be applied as a radiosensitizer in radiotherapy. Sensitization enhancement ratio (SER) quantified on MCF-7 cells 
demonstrated the highest enhancement from the highest concentration of BiONPs with SER of 2.29 and 1.42, for 10 MV photon beam 
and 6 MeV electron beam, respectively. In contrast to ROS production without radiation, the ROS induced from radiotherapy beams 
were found to be dose-dependent and play significant roles in radiosensitization effect. In conclusion, BiONPs could improve clinical 
radiotherapy, and further radiobiological characterization is crucial for future clinical translation. 
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I. INTRODUCTION 
Materials in nanometer scales have long existed in our 
nature. However, only recently, that systems and technology 
have advanced towards nanoscales application in many 
fields, including medicine. Nanosized materials such as 
nanoparticles (NPs) are defined as an aggregation of matter 
with a radius of not more than 100 nm [1]. Metal NPs such 
as gold started to be used in biomedical applications due to 
their intriguing biological properties [2]. Currently, 
nanotechnology has hugely contributed in prevention, 
diagnostics, and treatments of diseases, especially in drug 
delivery, tissue engineering, magnetic resonance imaging, 
cancer therapy, tissue repair, and cellular therapy [3], [4].  
In radiotherapy, therapeutic nanoparticles are the growing 
trends in research, and the NPs with high atomic numbers (Z) 
have been extensively investigated for their excellent 
radiosensitizing effects in cancer treatment. High dose of 
radiation in eliminating cancer cells usually affected the 
surrounding healthy tissue and induced complication [5]. 
The presence of NPs in a tumor would help local absorption 
of the radiation energy and concentrate more dose at the 
target site, thus contributed to the DNA damage of the 
cancer cells [6].  
In a clinical setting nowadays, radiosensitizers used are 
usually in the form of chemotherapy drugs such as cisplatin, 
capecitabine, and 5-fluorouracil [7]–[9]. However, one of the 
major concerns is their cytotoxicity effects on healthy 
normal cells. The drug used would be widely taken up by 
both normal and cancer tissues, and the tissues would be 
affected by both chemotherapy and radiotherapy [8]. An in 
vivo research demonstrated that radiotherapy, in combination 
with cisplatin had caused significant systemic toxicities [7]. 
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Also, a few clinical cases reported that capecitabine and 5-
fluorouracil could cause hand-foot syndrome, diarrhea, lung 
hemorrhage, as well as life-threatening toxicity [10], [11]. 
Metal NPs have begun to be considered as safer 
alternatives as radiosensitizers. Since NPs did not dissolve in 
solution, the entry to normal capillaries and vasculature are 
limited, and the half-life of NPs in the human body is longer 
than the usual drugs [8]. Carbon black, zinc dioxide, silicon 
dioxide and single-wall carbon nanotube NPs with sizes 
range between 8 to 21 nm were tested on primary fibroblast 
cell BALB/3T3 demonstrated low cytotoxic properties (cell 
viability more than 80 %) when treated with concentrations 
of 5 and 10 µg/ml [12]. Even a 60 µg/ml of bismuth 
subsalicylate concentration had shown only 6 % of 
cytotoxicity on gingival fibroblast HGF-1 cells [13].  
NPs of different types have been preclinically investigated 
for their potential application in radiotherapy. Gold NPs are 
one of the most widely studied nanoparticles found to 
enhance the radiation dose at kilovoltage [14], clinical 
megavoltage photon beam [15], [16], synchrotron 
microbeam [6] and 192Ir brachytherapy [17]. Supporting the 
inert and biocompatible properties of Gold NPs, cytotoxicity 
assessment indicate more than 75 % of cell viability 
depending on the NPs concentrations and the cell types [3], 
[14]. Apart from gold NPs, gadolinium oxide NPs were 
tested on CT26 cells using 50 keV synchrotron radiation and 
had been found to enhance ROS production, suggesting the 
subsequent dose enhancement effect [18]. Moreover, iron 
oxide NPs expressed the dose enhancement factor (DEF) of 
2.5 when tested on T24 bladder cancer cells using a clinical 
10 MV photon beam [19]. 
While most studies focus on engineered metal NPs 
involved gold, bismuth has also begun to be investigated as 
an alternative material due to its low toxicity and cost-
effective attributes [20]. Bismuth and its complexes are 
found to have many properties such as antibacterial [13], 
antiproliferative, antimicrobial [21] and high radiation 
absorption coefficient that make it suitable as contrast agents 
in X-ray computed tomography for medical imaging [20]. 
Bismuth oxide NPs (BiONPs) have been introduced as a 
radiosensitizer because the presence of bismuth may trigger 
additional retention, absorption, and scattering of the 
radiation at the cancer site [22], and thus demonstrated a 
higher enhancement of the dose, in comparison to other 
types of NPs [23]. Cytotoxicity effects have been reported in 
previous literature indicating 50 % of cells inhibition 
concentration values (IC50) caused by BiONPs on HepG2 
liver, NRK-52E kidney, Caco-2 colorectal and A549 lung 
cell lines [24]. Another study conducted on Chang liver cells 
found that the BiONPs cytotoxicity was associated with the 
temperature during BiONPs synthesis [25]. In regards to 
their attractive biocompatibility profile, the potential of 
BiONPs as radiosensitizer has been investigated in vitro, in 
vivo as well as in silico and phantoms studies which 
presented interesting results [26]–[28]. The researches above 
though did not investigate the applicability of the BiONPs 
on the breast cancer radiotherapy, and this report will be the 
first empirical precedent to apply BiONPs for clinical 
megavoltage beams.  
In this study, we intend to investigate the fundamental 
biological characteristic of BiONPs such as cytotoxicity, 
cellular uptake as well as reactive oxygen species (ROS) 
generation on normal and breast cancer cells, as the 
preliminary analysis for the development of novel non-toxic 
radiosensitizer. Later we quantify the radiosensitization 
effects and ROS production of BiONPs after treatment with 
clinical radiotherapy beams to observe the actual feasibility 
of the BiONPs application in breast cancer radiotherapy. 
II. MATERIALS AND METHODS 
A. BiONPs Preparation 
The experiments were conducted using four different 
sizes of rod-shaped BiONPs which are 60, 70, 80 and 90 nm. 
We chose the sizes of less than 100 nm following the 
definition of nanomaterials by Stewart [26]. On the other 
hand, there are research that studied the sizes of 
nanoparticles with high gap such as 10 nm over 300 nm [29], 
25 nm over 50 nm [30], and 10 over 100 nm[31]. Hence our 
study would like to clarify the influence of the small 
difference between the sizes. Thus, we used these 4 sizes. 
The BiONPs of various sizes were synthesized using the 
hydrothermal method and characterized as reported in 
previous literature [32], [33]. The BiONPs were diluted with 
Dulbecco’s Modified Eagles Medium (DMEM, Gibco, USA) 
and stored in 4 ºC for in-vitro study. 
B. Cell culture: MCF-7, MDA-MB-231, and NIH/3T3 
MCF-7 (human breast adenocarcinoma), MDA-MB-231 
(human mammary gland carcinoma) and NIH/3T3 (mouse 
embryonic fibroblast) cell lines were used in the in-vitro 
study. All types of cell lines were cultured in Dulbecco’s 
Modified Eagles Medium (DMEM, Gibco, USA), 
supplemented with 5 % of fetal bovine serum (FBS) (Gibco, 
USA) and 1% penicillin-streptomycin (Gibco, USA). Sub-
culturing of the cell lines was performed by detaching the 
adherent cells using 0.025 % trypsin-EDTA (Gibco, USA), 
and the cells were maintained by routine passage every two 
to three days. Phosphate Buffered Saline (PBS) (Gibco, UK) 
was used to wash the debris and floated dead cells in the 
flasks. Cell incubator humidified with 5% CO2 in 37oC was 
used to keep the cells grown. 
C. In Vitro Cytotoxicity Effects 
1) Cell Viability Measurement with Prestoblue Assay 
(Pre-Irradiation):  The cellular effects of the BiONPs on cell 
viability without irradiation were measured using Prestoblue 
assay, as a preliminary study to infer the significance of 
BiONPs on the cells. The study was conducted by culturing 
approximately 2 x 104 of cells per ml in 96 wells plates until 
reaching 70 to 80 % confluency. The cells were then treated 
with 0.5, 0.05, 0.005, 0.0005 and 0.00005 mMol/L of 
BiONPs for 24, 48 and 72 hours respectively. Measurements 
of the viability of the cells were performed by replacing the 
cells media with 90 µl of fresh media and adding 10 µl of 
Prestoblue reagent (Invitrogen, USA). The cells were 
incubated with Prestoblue for around 4 hours. The 
fluorescence was measured using a microplate reader at 535 
nm excitation and 615 nm emission wavelength. 
2) ROS induced by BiONPs Measurement (Pre-
Irradiation): The ROS produced by BiONPs were measured 
according to the protocol reported in previous literature [12], 
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[34], as a pilot study to analyze the appropriate use of 
BiONPs. The 5 x 104 cells per ml were cultured in 96 wells 
plates and incubated overnight until it reached 50-70 % 
confluency. After incubation, the cells were treated with 
BiONPs, washed with PBS, and 10 µl of 2’, 7’- 
dichlorodihydrofluorescein diacetate (DCFH2-DA, Sigma-
Aldrich) diluted in DMSO was added in each well. Then, the 
cells with light-sensitive DCFH2-DA were incubated at 37 
°C in the dark for around 60 minutes.  The fluorescence was 
then determined at 485 nm excitation and 530 nm emission 
using microplate reader, immediately after treatment, 3.5 
hours, 6 hours, and 24 hours. 
D. BiONPs Uptake Measurement 
The BiONPs uptake was measured using flow cytometry-
based on a previously established method [35], as a prelude 
investigation to pre-determine the relevancy of the BiONPs 
application. Cells were counted to be 1 x 104 cells per ml 
and then were cultured in 6-well plates and incubated at 37 
°C for 24 hours. After incubation, the cells were washed 
gently with PBS and treated with 0.5 mMol/L of 60 nm 
BiONPs for 24 hours. In this study, we only measured the 
uptake of 60 nm BiONPs. The cells were rewashed with 
PBS, before being trypsinized from the plates to prepare the 
cell suspension in flow cytometry tubes. 1 ml of culture 
medium was added to the cells suspension to neutralize the 
trypsin. The cells were centrifuged at 1500 rpm for 5 min 
and washed with PBS twice. Lastly, the cells were 
suspended in PBS with a maximum volume of 400 µl and 
left on ice until the time for analysis. Flow cytometry was 
performed using a blue fluorescent filter (FACS Canto II, 
BD Biosciences, US). 
E. Quantification of Radiosensitization Effects for 
Megavoltage Radiotherapy 
1) Sensitization Enhancement Ratio Measurement: The 
effects of the megavoltage radiotherapy in combination with 
BiONPs were evaluated on MCF-7 cells and 60 nm BiONPs. 
MCF-7 cell samples were prepared with and without 
BiONPs of 60 nm size with the concentration of 0.05, 0.25, 
and 0.05 µMol/L. The samples were exposed to radiation 
doses from 0 to 10 Gy irradiated with 6 and 10 MV photon 
beams, as well as 6 and 12 MeV electron beams generated 
from a medical linear accelerator (Elekta Synergy, Sweden) 
at Advanced Medical and Dental Institute, Universiti Sains 
Malaysia. The irradiation was done at a dose rate of 599 
MU/min. Clonogenic assays determined cell survival after 5 
days. The cell survival for samples with and without 
BiONPs was then plotted and fitted according to the linear-
quadratic (LQ) model using OriginPro 8.5 software. The 
parameters from the LQ formula given by equation 1 were 
analyzed.   
 
S = exp – (αD + βD2)                                                  (1) 
 
In the equation, S is the survival fraction and D is the dose 
in Gray. The model represented by the linear component 
[exp (- αD)] and quadratic component [exp (-βD2)] where α 
indicate single hit double-strand break of two chromosomes 
and β show double hits that induce double-strand break of 
two chromosomes. 
The radiosensitization effects were quantified by 
calculating the sensitization enhancement ratio (SER). 
Equation 2 shows the SER calculation: 
 
  (2) 
 
2) ROS induced by BiONPs Measurement (Post-
Irradiation): Measurements of ROS caused by BiONPs 
under irradiation with megavoltage radiotherapy beam were 
performed on MCF-7 cells and 60 nm BiONPs. ROS was 
evaluated by using cells cultured in 96 well plates 
(approximately 1 x 104 cells per well) incubated for 24 hours.  
The cells were then treated with BiONPs with different 
concentrations (0.5, 5.0, and 50.0 µMol/L) and DCFH-DA 
reagent was added in each well to make up a final 
concentration of 50 μM. The cells were irradiated using a 
similar irradiation setup with SER measurement. The ROS 
generations after the irradiation were measured using 
microplate reader (FLUOstar Omega, BMG Labtech, 
German) with an excitation of 485 nm and an emission of 
520 nm immediately after irradiation. 
F. Statistical Analysis 
The data were expressed as the mean ± standard error of 
the mean (SEM) and mean ± standard deviation (SD). All 
graphs and statistical tests were plotted and performed using 
OriginPro 2018 software (OriginLab Corporation, US). 
III. RESULT AND DISCUSSION 
A. In Vitro Cytotoxicity Effects 
1) Cell Viability Measurement with Prestoblue Assay 
(Pre-Irradiation): Cytotoxicity effects of 60, 70, 80 and 90 
nm BiONPs of different concentration is shown in Fig. 1. All 
cells show more than 80 % cell viability when treated with 
all different sizes and concentrations of BiONPs. However, 
the NIH/3T3 and MDA-MB-231 cells show more than 20 % 
of cell death at 48 and 72 hours when treated with 0.5 
mMol/L of 70, 80, 90 nm of BiONPs, as depicted in Fig. 1 
(B, C, D, J, and L). Treatment with 0.05 and 0.5 mMol/L of 
70, 80, 90 nm BiONPs on MCF-7 cells as shown in Fig. 1 (F) 
also indicate cell death more than 20 % even at 24 hours 
incubation. Meanwhile, 60 nm BiONPs are biocompatible 
on cancer and normal cells for all concentrations tested after 
24, 48 and 72 hours. The results presented more than 80 % 
cell viability against both normal fibroblast and breast cancer 
cell lines, in Fig. 1 (A, E and I). The 60 nm BiONPs at 0.005 
mMol/L of concentration particularly are found to induce 
less toxicity in comparison to other sizes and concentration. 
Thus, the 60 nm BiONPs is considered the optimal size for 
potential application as a radiosensitizer.  
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 The results demonstrated the cytotoxicity dependency on 
BiONPs size. Smaller nanoparticles (NPs) have a larger 
surface-area-to-volume ratio and hence induced higher 
surface reactivity and cytotoxicity [36].  Several studies also 
found that cytotoxicity of several types of NPs was size-
dependent. Studies conducted on large ranges NPs sizes, 
such as 10 to 300 nm silica and gold NPs [29], 50 to 80 nm 
BiONPs [26], 3 to 50 nm gold NPs [30], 10 to 100 nm silver 
NPs [31] indicate effects of size on cytotoxicity. A study 
showed that 50 nm NPs were only localized in the 
cytoplasm, not the nucleus. Thus the low toxicity as the 
membrane damages was not high [30]. These results were in 
agreement with our current findings in which BiONPs in the 
diameter sizes of 60, 70, 80 and 90 nm could only cause 
minimal cytotoxicity. However, the cytotoxicity of BiONPs 
is also dependent on incubation time and cell types as 
observed in this study. 
Prestoblue reagent was used for the cytotoxicity study, as 
it was considered as a fast and non-toxic assay [37], [38]. 
The detection of cell viability depends on the functions of 
the mitochondrial enzymes within the live cells which 
reacted with the rezasurin compound [37]–[39] The 
fluorescent reduced formed of rezasurin changed the color of 
the cell media and could be measured by both fluorescence 
and absorbance [40]. A quantitative study stated that 
Prestoblue gives a stronger fluorescent signal than Alamar 
blue assay[41]. Prestoblue assay is a ready-to-use assay as it 
only needed one single step compared to MTT and LDH 
release assays [39]. It is also more sensitive compared to the 
MTT assay as the latter required a longer time to be able to 
detect the cells as well as toxic to the cells [38], [40].  
2) ROS induced by BiONPs Measurement (Pre-
Irradiation): The presence of oxidative stress yielded by the 
NPs in the cell would produce the free radicals that will 
possibly attack the DNA in the cells [12]. Fig. 2 shows the 
intercellular generation of ROS due to the presence of 
BiONPs. After treatment with different sizes and different 
concentrations of BiONPs on the NIH/3T3 cells, it is 
observed that the formation of ROS is not affected by the 
size and concentration of NPs (Fig. 2A and 2D).  
Nevertheless, the ROS measured at 24 hours of treatment are 
found to be lower than at 6 hours in normal NIH/3T3 cells. It 
may suggested that ROS decrease after 6 hours and this 
could be the reason of the minimal toxicities caused by the 
BiONPs on NIH/3T3 cells after 24, 48, and 72 hours periods 
(Fig. 1). This finding is supported by Zhu et al. in which 
they hypothesized that the upregulated endogenous ROS 
production in normal cells due external stress would not 
Fig. 1 Cytotoxicity assay of different sizes (60, 70, 80, and 90 nm) and concentrations (0.00005, 0.0005, 0.005, 0.05, and 0.5 mM) of BiONPs-treated 
cells. (A) (B) (C) and (D) BiONPs treatment on NIH/3T3 cells. (E), (F), (G) and (H) BiONPs treatment on MCF-7 cells. (I), (J), (K) and (L) BiONPs 
treatment on MDA-MB-231 cells.  The x-axis depicts the concentrations, in mM. Y-axis shows the percentage of active cells. Legends indicate the hours 
of BiONPs treatment incubations, in hours. Each error bar represents the standard error of mean (SEM). 
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exceed the toxic threshold of ROS [42]. The antioxidant 
enzymes within the cells such as catalase (CAT), superoxide 
dismutase (SOD), and gluthathione peroxidase (GPx) would 
detoxify the ROS [43]–[45]. Thus, the redox activity 
happened and lowered back the ROS level [42].  
Furthermore, after treatment with different sizes and 
different concentrations of BiONPs on MCF-7 cells, the 
DCF fluorescence elevated up to 3.5 hours, before it 
decreased afterward. In Fig. 2 (B), the ROS continued to 
deplete as time increase, however, in Fig. 2 (E), the 
percentage of ROS started to increase again at 24 hours. The 
induced ROS formation is in a time-dependent manner. The 
previous study had also noted that MCF-7 cells could cause 
time-dependent cytotoxicity due to ROS production [4]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 ROS measurement of BiONPs on NIH/3T3, MCF-7, and MDA-MB-231 cells. The treated cells were compared to control cells treated with DCFH-DA 
only (positive control), 100 % DCF fluorescent. Graphs A, B and C were based on 0.5 mM of different BiONPS sizes, while graphs D, E and F were based on 
different concentrations of 60 nm BiONPs. Each error bar represents the standard error of mean (SEM). 
 
On the other hands, the ROS generation in MDA-MB-231 
cells generally occurred in the same increasing pattern from 
0 to 24 hours. The percentages of DCF detected were also 
within the range of 91 to 106 %, though with different sizes 
and different concentrations. Most of the cells either induced 
ROS in lower percentage or slightly higher than that of 
positive control (100 %).  
For this study, we deduced that the ROS formation did not 
play a critical role in the cytotoxicity of the BiONPs with 
slightly different diameter sizes. The findings in the present 
study are in agreement with a previous study which implied 
that any mechanism caused by the ROS generation would 
not significantly affect the DNA of the cells and thus, ROS 
generation was only the secondary force to the onset of 
cytotoxicity [46]. Another research also had identified 
bismuth oxide nanoceramics as ROS scavengers depending 
on the NPs production process [26]. Meanwhile, a study on 
erythrocytes revealed that a bismuth-based compound has 
antioxidant activity and offered protection against the 
toxicity by other particles [47]. Even though the latest 
investigation showed BiONPs could induce significantly 
high ROS but the lowest BiONPs concentration used was 50 
µg/ml [48], while our study only used 0.5 µM or 
approximately 0.233 µg/ml of BiONPs as the highest 
concentration. Hence, it is suggested that the treatment of 
BiONPs on the cells in our study did not induce high 
oxidative stress and could be considered as biocompatible 
with the cells.  
B. BiONPs Uptake Measurement 
Fig. 3 illustrates the localization of 60 nm of BiONPs 
treatment on cells, obtained via flow cytometric analysis. 
The method of nanoparticle uptake detection by flow 
cytometry was already established and widely used in many 
studies. It is considered as a robust high throughput method 
and required only a couple of seconds for a maximum of 10 
to 50 thousands cells [35], [36], [49]. The preparation time is 
more simple and fast, while the results generated are in high 
quality and statistically relevant as the cells are individually 
analyzed in comparison to the transmission electron 
microscope and inductively coupled plasma mass 
spectrometry [35], [49], [50]. The use of flow cytometry for 
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nanoparticle internalization also could simultaneously 
explored other parameters such as cell cycles, cells 
apoptosis, cells necrosis, DNA damages, ROS generation, as 
well as cell types differentiation, in which appropriate 
fluorescent probes are needed respectively [35], [36], [49], 
[51]. In Fig. 3, each box is gated by side scattering (SSC) 
and forward scattering (FCS). The SSC and FSC represent 
the granularity and the size of the cells, respectively [26], 
[49].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Q1 and Q3 quadrants were distinguished as a dead 
cell or cell debris population, while Q2 and Q4 quadrants 
portrayed live cells population. Previous studies stated that 
the uptake of the NPs would not influence the FSC, but it 
would depend on the size of the NPs [26], [52], [53].  
The NIH/3T3, MCF-7 and MDA-MB-231 cells that were 
treated with 0.5 mMol/L of 60 nm BiONPs showed a 
substantial increase in granularity, which leads to a higher 
percentage at Q2 population (13 to 35 %), compared to 
control cells (1 to 4 %). The rise of Q2 populations 
suggested that the BiONPs localized on the surface of the 
cells and had been internalized in the cells. In the previous 
study, the highest amount of cellular uptake of NPs ensued 
at the size of 50 nm. NPs cellular uptake would decrease for 
larger NPs [38]. 
Incorporation of NPs within the cells will significantly 
induce cytotoxicity and could cause irreparable DNA 
damages [31], [53], [54]. NPs size plays essential roles in the 
cellular NPs uptake. In this study, 60 nm BiONPs are found 
to be biocompatible that could be due to that most of these 
sizes of BiONPs were mostly bound to the surface of the 
cells and a few NPs were internalized inside cells. This 
assertion can be associated with the minimal cytotoxicity 
and high biocompatibility of 60 nm of BiONPs on both 
healthy and breast cancer cells.   
C. Radiosensitization Effects for Megavoltage Radiotherapy 
1) Sensitization Enhancement Ratio Measurement: 
Given the primary purpose was to used BiONPs as a 
radiosensitizer with low toxicity, lower concentrations of 60 
nm BiONPs (0.05, 0.25, and 0.5 µM) were tested on MCF-7 
cell. Fig. 4 depicts the cell survival curves for MCF-7 cells 
irradiated with both photon and electron beams. Generally, 
the presence of BiONPs during the radiotherapy had 
enhanced the radiosensitization effect of the radiation, thus 
lowers the survival of the cancer cells. The survival curves 
also indicate that the radiosensitization on the cells is 
dependent on the BiONPs concentration, beam quality, and 
radiation dose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Survival curves of MCF-7 cells with three concentrations of 60 nm of BiONPs, irradiated with 6 MV and 10 MV 
photon beam, as well as 6 MeV and 12 MeV electron beam, fitted to linear quadratic model. Each error bar represents 
Fig. 3 Cellular uptakes due to the treatment with 0.5 mMol/L of 60 nm 
BiONPs on 3 types of cell lines; NIH/3T3, MCF-7 and MDA-MB-231 
cells. Increments of percentage in quadrant Q2 are observed indicating the 
occurrence of nanoparticle uptakes. 
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The effects are quantified as sensitization enhancement 
ratio (SER) values for photon and electron beams and 
tabulated in Table I. The increasing value of SER indicates 
the radiosensitization effects are dependent on BiONPs 
concentration and radiation energy. The concentration of 0.5 
µM of BiONPs, which give the highest SER value for each 
energy, had caused the most cell death in this study with a 
lower radiation dose compared to the other BiONPs 
concentrations. These findings are supported by other studies 
on BiONPs [27], [28]. As a higher amount of BiONPs 
present, more radiation interactions might transpire against 
cancer cells. The penetration power also increases as the 
energy of the beam used were higher [28], [55]. 
A 3D phantoms study had demonstrated that the BiONPs 
was effective in enhancing the ionizing radiation dose of 
megavoltage x-ray beams with an enhancement factor of 
1.25 [27]. Besides, a Monte Carlo simulation of BiONPs 
irradiations had revealed a high SER range around 16 to 19. 
The difference in the SER values was due to the difference 
in the concentration of BiONPs used. Nonetheless, the result 
from the present study can be correlated with the previous 
studies as mentioned earlier in which they predicted that the 
presence of BiONPs would increase the effective atomic 
numbers, absorption probabilities and radiation scattering 
[22], [28]. The internalized BiONPs reactions with the 
radiation beam would enhance the damaging effects on the 
DNA of cancer cells.  
It is mentioned that interactions between radiation 
energies and high Z materials would initiate photoelectric 
absorption, Compton effect and pair productions [3]. The 
effects which mostly depends on the atomic numbers Z is the 
photoelectric effect [56]. High atomic numbers would 
elevate the photoelectric absorption, thus released more ions 
and free radicals, leading to cell damages and cell deaths 
[56]. However, previous works demonstrated that 
photoelectric interactions are not dominant for megavoltage 
beam, as higher energy would cause a higher Compton 
scattering [27], [57]. In the presence of high atomic number 
element, such as bismuth, the dominant interaction at the 
energy of more than 5 MeV would be the electron-positron 
pair production [26]. These interactions would contribute to 
the breakage of the single and double strands of the DNA. 
More importantly, the SER values of BiONPs 
radiosensitization from the present study were higher than 
aforementioned works on different metal NPs, such as gold 
NPs with DEF of 1.31 and 1.54 when using 10 MV photon 
beam and brachytherapy respectively [15], [17], tagged gold 
NPs with DEF of 1.25, and combination of gold NPs with 
cisplatin with DEF of 1.14 at 225 kVp using small animal 
irradiator [7]. The results from this study are also in close 
agreement with another BiONPs study on 9L gliosarcoma 
cells which presented SER of 1.25 and 1.48 for 125kVp and 
10 MV energies [23]. Future studies are currently underway 
to evaluate the radiosensitization effect of 60 nm BiONPs 
using other radiation energy and beams. 
Nevertheless, this study will open the pathways to 
decrease the mortality rate of breast cancer patients 
specifically. Enhancement of the radiation effects with the 
radiosensitizer would decrease the prescribed radiation doses 
to the patients. Therefore, the effect of radiation on nearby 
healthy organs might also be reduced and possibly lowered 
the likelihood of breast cancer patients to contract radiation-
induced diseases which might involve heart, lung, liver and 
esophagus. Ultimately, the future clinical applications that 
emanate from this study may increase the life span of the 
breast cancer patients. 
TABLE I 
THE CALCULATED SER FOR DIFFERENT CONCENTRATIONS OF 60 NM OF 
BIONPS IRRADIATED WITH PHOTON AND ELECTRON BEAMS. 
Types of 
Beam Energy 
BiONPs 
Concentration (µM) SER 
Photon  
6 MV 
Control 1.00 
0.05 1.07 
0.25 1.42 
0.50 1.88 
10 MV 
Control 1.00 
0.05 1.45 
0.25 1.66 
0.50 2.29 
Electron  
6 MeV 
Control 1.00 
0.05 1.13 
0.25 1.33 
0.50 1.42 
12 MeV 
Control 1.00 
0.05 1.05 
0.25 1.13 
0.50 1.22 
 
2) ROS Measurement induced by Radiation: Ionizing 
radiations are expected to disrupt the cancer cells 
progression either by direct radiation energy or by the 
mechanism of ROS indirectly [45]. Fig. 5 illustrates the 
intracellular ROS generation due to irradiation with photon 
and electron beams in the presence of different 
concentrations of BiONPs at 2,4 and 8 Gy of radiation dose.  
The percentage of ROS generated by all doses of photon 
and electron beams together with all concentrations of 
BiONPs are near and above 100 % in comparison to control 
without BiONPs. The highest concentration of BiONPs 
could commence the highest sensitization enhancement and 
elicited a higher percentage of ROS, as supported by a 
previous research work [18]. However, some irregularities 
are shown in Fig. 5 (A) and (D) in which the induction of 
ROS level after the irradiation were slightly lower than 
100 % when treated with a dose of 2 Gy and 4 Gy. 
The typical ROS level in cancer cells is stated to be in a 
higher amount than ROS in normal cells [45]. The 
appearance of other elements such as NPs and radiation ions 
could have boosted or reduced the intracellular ROS level. It 
had been established that radiotherapy on cancer cells would 
yield more ROS and subsequently damage the DNA of the 
cancer cells.[45].  
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 Besides, in the presence of NPs, most of the radiation 
energy is hypothesized to be absorbed into the cells by the 
NPs [6], [18]. As one of the high atomic Z elements, 
BiONPs could promote the photoelectric effects during the 
radiation, which in return produced a more elevated amount 
of ROS, leading towards increment of ROS and the cells 
impairments [18], [58]. Apart from that, there will be a 
minority of electrons that would evade the NPs absorption, 
further reacted with the surrounding and formed more ROS 
[18]. 
In this present study, it is assumed that the BiONPs that 
were internalized would also absorb the majority of the 
radiation dose. Then, the radiation interaction which was 
predominantly Compton effect was triggered. ROS will be 
generated and interact with the cancer cells’ DNA and hence 
cause damage. Results of the ROS measurements were 
attuned with the SER value attained in Table 1. 
IV. CONCLUSIONS 
This study highlights the importance of biological 
characteristics such as cytotoxicity, cellular uptake and ROS 
generation of rod-shaped BiONPs as a means to fully 
develop their properties as an alternative radiosensitizer. The 
current radiosensitizers used in radiotherapy are known to 
cause several side effects on healthy cells. Apart from being 
a high Z material, the BiONPs are found to be not toxic 
especially for 60 nm diameter size BiONPs. The BiONPs are 
also found to be suitable as a radiosensitizer for clinical 
radiotherapy on breast cancer cells as the results show the 
enhancement of radiosensitization and ROS generation 
induced by the BiONPs, which could increase the 
radiotherapy efficiency for the cancer treatment. Further 
investigation using various type of beam quality is required 
to fully understand the application of BiONPs in clinical 
settings.  
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